Media headlines about Checkpoint Therapeutics (NASDAQ:CKPT) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.6672006988645 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Zacks: Checkpoint Therapeutics Inc (CKPT) Given $15.50 Average Target Price by Brokerages (americanbankingnews.com)
- Small-Cap Snapshot: Fitness drink maker Celsius Holdings hits 52-week low after 2Q disappoints (proactiveinvestors.com)
- Checkpoint Therapeutics up 23% (seekingalpha.com)
- HC Wainwright Reiterates “Buy” Rating for Checkpoint Therapeutics (CKPT) (americanbankingnews.com)
- Checkpoint Therapeutics (CKPT) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS (americanbankingnews.com)
A number of equities analysts recently weighed in on CKPT shares. ValuEngine raised shares of Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research cut shares of Checkpoint Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Checkpoint Therapeutics in a research report on Friday, May 11th.
Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. Checkpoint Therapeutics had a negative net margin of 2,367.51% and a negative return on equity of 126.68%. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.37 million. equities analysts predict that Checkpoint Therapeutics will post -1.18 earnings per share for the current year.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.